Zimu Wang1, Ping Zhan1, Yanling Lv2, Kaikai Shen3, Yuqing Wei1, Hongbing Liu1, Yong Song1. 1. Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China. 2. Department of Respiratory Medicine, Jinling Clinical Medical College of Nanjing Medical University, Nanjing 210002, China. 3. Department of Respiratory Medicine, Wannan Medical College, Wuhu 241000, China.
Abstract
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) is related to prognosis in non-small cell lung cancer (NSCLC). However, no consensus on the relationship of pretreatment NLR and survival outcomes of systemic therapy in NSCLC exists. This meta-analysis investigated the prognostic role of pretreatment NLR during systemic therapy for NSCLC, including chemotherapy, immunotherapy and targeted therapy. METHODS: PubMed, Web of Science and Cochrane Library databases were systematically searched up to April 09, 2019. Hazard ratios (HRs) with their 95% confidence intervals (CIs) were pooled to investigate the association of pretreatment NLR with progression-free survival (PFS) and overall survival (OS). RESULTS: In total, 27 articles with 4,298 participants were selected. The pooled results showed that elevated pretreatment NLR was associated with inferior PFS (HR, 1.45, 95% CI, 1.28-1.66) and OS (HR, 1.63, 95% CI, 1.43-1.84) during systemic therapy. Subgroup analyses according to the treatment strategy suggested that higher pretreatment NLR was significantly associated with shorter survival in all therapies, including chemotherapy (PFS HR, 1.74, 95% CI, 1.39-2.17; OS HR, 1.73, 95% CI, 1.26-2.36), immunotherapy (PFS HR, 1.53, 95% CI, 1.27-1.84; OS HR, 2.50, 95% CI, 1.60-3.89) and targeted therapy (PFS HR, 1.53, 95% CI, 1.04-2.25; OS HR, 1.92, 95% CI, 1.14-3.24). CONCLUSIONS: Pretreatment NLR is a promising prognostic indicator for NSCLC patients receiving systemic therapy, including chemotherapy, immunotherapy and targeted therapy.
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) is related to prognosis in non-small cell lung cancer (NSCLC). However, no consensus on the relationship of pretreatment NLR and survival outcomes of systemic therapy in NSCLC exists. This meta-analysis investigated the prognostic role of pretreatment NLR during systemic therapy for NSCLC, including chemotherapy, immunotherapy and targeted therapy. METHODS: PubMed, Web of Science and Cochrane Library databases were systematically searched up to April 09, 2019. Hazard ratios (HRs) with their 95% confidence intervals (CIs) were pooled to investigate the association of pretreatment NLR with progression-free survival (PFS) and overall survival (OS). RESULTS: In total, 27 articles with 4,298 participants were selected. The pooled results showed that elevated pretreatment NLR was associated with inferior PFS (HR, 1.45, 95% CI, 1.28-1.66) and OS (HR, 1.63, 95% CI, 1.43-1.84) during systemic therapy. Subgroup analyses according to the treatment strategy suggested that higher pretreatment NLR was significantly associated with shorter survival in all therapies, including chemotherapy (PFS HR, 1.74, 95% CI, 1.39-2.17; OS HR, 1.73, 95% CI, 1.26-2.36), immunotherapy (PFS HR, 1.53, 95% CI, 1.27-1.84; OS HR, 2.50, 95% CI, 1.60-3.89) and targeted therapy (PFS HR, 1.53, 95% CI, 1.04-2.25; OS HR, 1.92, 95% CI, 1.14-3.24). CONCLUSIONS: Pretreatment NLR is a promising prognostic indicator for NSCLC patients receiving systemic therapy, including chemotherapy, immunotherapy and targeted therapy.
Authors: Youngjoo Lee; Sun Hye Kim; Ji-Youn Han; Heung Tae Kim; Tak Yun; Jin Soo Lee Journal: J Cancer Res Clin Oncol Date: 2012-07-07 Impact factor: 4.553
Authors: Helen H W Chen; Jiang-Jou Yan; Wen-Chung Chen; Macus Tien Kuo; Yu-Hsuan Lai; Wu-Wei Lai; Hsiao-Sheng Liu; Wu-Chou Su Journal: Lung Cancer Date: 2011-07-23 Impact factor: 5.705
Authors: Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir Journal: J Natl Cancer Inst Date: 2014-05-29 Impact factor: 13.506
Authors: R J van Soest; A J Templeton; F E Vera-Badillo; F Mercier; G Sonpavde; E Amir; B Tombal; M Rosenthal; M A Eisenberger; I F Tannock; R de Wit Journal: Ann Oncol Date: 2014-12-15 Impact factor: 32.976
Authors: Alex K Bryant; Kamya Sankar; Garth W Strohbehn; Lili Zhao; David Elliott; Angel Qin; Sarah Yentz; Nithya Ramnath; Michael D Green Journal: Lung Cancer Date: 2021-12-02 Impact factor: 5.705
Authors: Stephan Rheinheimer; Claus-Peter Heussel; Philipp Mayer; Lena Gaissmaier; Farastuk Bozorgmehr; Hauke Winter; Felix J Herth; Thomas Muley; Stephan Liersch; Helge Bischoff; Mark Kriegsmann; Rami A El Shafie; Albrecht Stenzinger; Michael Thomas; Hans-Ulrich Kauczor; Petros Christopoulos Journal: Cancers (Basel) Date: 2020-04-23 Impact factor: 6.639